Revenue and Financial Performance - Consolidated revenue for the year ended December 31, 2025, was $16,398 thousand, a 32% decrease compared to $24,207 thousand for the year ended December 31, 2024 [240]. - Gross profit for the year ended December 31, 2025, was $6,321 thousand, with a gross margin of 38.5%, up from 35.8% in 2024 [241]. - The Precision Logistics segment revenue decreased to $16,242 thousand in 2025 from $23,766 thousand in 2024, primarily due to the termination of the ProActive services agreement [240]. - Net loss for the year ended December 31, 2025, was $4,905 thousand, compared to a net loss of $3,824 thousand in 2024, with a loss per share of $0.39 [248]. - Cash provided by financing activities for the year ended December 31, 2025, was $3,660 thousand, compared to cash used of $616 thousand in 2024 [251]. - Research and development expenses decreased to $20 thousand in 2025 from $70 thousand in 2024, reflecting fewer projects in the Authentication segment [244]. - Segment management and technology expenses decreased by $2,316 thousand to $3,138 thousand for the year ended December 31, 2025, compared to $5,454 thousand in 2024 [242]. - The company recorded an intangible asset impairment charge of $2,788 thousand and a goodwill impairment charge of $1,062 thousand for the year ended December 31, 2025 [246]. - The Company recorded a goodwill impairment charge of $1,062 thousand during the year ended December 31, 2025, due to a triggering event related to the Precision Logistics segment [269]. - An intangible impairment charge of $2,788 thousand was recorded during the year ended December 31, 2025, as certain intangible assets were deemed impaired [271]. Strategic Partnerships and Services - The company expects to begin broadly offering Premium and Direct Premium services to customers of its new Strategic Partner in Q2 2026 [208]. - The company ceased providing ProActive and Premium services to its prior carrier partner in 2025 but continues to offer Direct Premium services [207]. - The company anticipates ProActive services revenue to recover over several quarters following the new Program Agreement with a Strategic Partner [240]. - VerifyMe's service offerings include customized reporting for trend analysis and post-delivery services to enhance customer processes [205]. - The proprietary PeriTrack® dashboard provides real-time visibility into shipping activities and supports supply chain stakeholders [211]. - Over 95% of the Company's revenue is derived from logistics management for time and temperature-sensitive packages [266]. Mergers and Acquisitions - The merger with Open World Ltd. is expected to result in existing stockholders retaining approximately 10% of the post-merger shares, while Open World shareholders will receive about 90% [213]. - The merger agreement includes customary covenants, including conducting business in the ordinary course and restrictions on certain transactions [214]. - The company has agreed to maintain a Closing Net Cash of no less than $1 million as a condition for the merger [217]. Employment Agreements - Adam Stedham's new employment agreement includes an annual base salary of $300,000 with a potential bonus of up to 50% based on performance [224]. - Jennifer Cola's employment agreement includes an annual base salary of $180,000 with a potential bonus of up to 50% based on performance, along with 130,000 restricted stock awards [227]. Financial Obligations and Compliance - The Company is not in compliance with all covenants under the PNC Facility as of December 31, 2025, but received a waiver for certain events of default [260]. - The Company expects to fund operations for the next 12 months through current financial resources and future revenue, with potential for additional debt or equity issuance [263]. - The PNC Facility includes a $1 million Revolving Line of Credit (RLOC) with no scheduled principal payments until maturity, and as of December 31, 2025, $0 was outstanding on the RLOC [258]. - A four-year Term Note for $2 million under the PNC Facility was paid in full as of January 21, 2025, with no future principal payments due [259]. - The Company entered into a Convertible Note Purchase Agreement for the sale of convertible promissory notes totaling $1,100 thousand, with $475 thousand purchased by related parties [257]. - As of December 31, 2025, the outstanding amount on the convertible debt was $750 thousand, with an interest expense of $61 thousand for the year ended December 31, 2025 [257]. Future Growth and Strategy - The Company anticipates growth through key acquisitions and organic growth strategies [263].

Financial Performance - Q2 GAAP revenues were $611.0 million, an increase of 7.1% from Q2 2025, driven by institutional buy-side and wealth management clients[5]. - Q2 GAAP diluted EPS was $3.59, down 4.5% from the prior year, while adjusted diluted EPS increased by 4.2% to $4.46[5][6]. - Revenues for the three months ended February 28, 2026, were $611,019, representing a 7.1% increase from $570,660 in the same period of 2025[26]. - Operating income for the same period was $184,961, slightly down by 0.3% from $185,492 in 2025[33]. - Net income decreased by 8.1% to $133,056 for the three months ended February 28, 2026, compared to $144,860 in 2025[33]. - Organic revenues for the three months ended February 28, 2026, were $606,176, reflecting a 6.8% increase from $567,543 in 2025[30]. - Adjusted operating income for the three months ended February 28, 2026, was $214,068, a 0.7% increase from $212,669 in 2025[33]. - Free cash flow for the three months ended February 28, 2026, is reported at $185,691 thousand, a 23.6% increase from $150,219 thousand in the prior year[37]. - Net cash provided for operating activities increased by 21.7% to $211,688 thousand compared to $173,955 thousand in the previous year[37]. Client Metrics - Client count increased to 9,101, with a net addition of 98 clients in the past three months, and user count rose to 241,352, an increase of 1,489 users[12]. Guidance and Projections - The company updated its fiscal 2026 guidance, expecting organic ASV growth of $130 million to $160 million and GAAP revenues in the range of $2,450 million to $2,470 million[18]. - Fiscal 2026 revenue guidance is projected between $2,450 million and $2,470 million[35]. - Adjusted operating income is expected to range from $840 million to $870 million, with adjusted operating margins of 34.0% to 35.5%[35]. - Net income guidance for Fiscal 2026 is between $555 million and $582 million, with adjusted net income ranging from $645 million to $670 million[35]. - Diluted earnings per share (EPS) is projected to be between $14.85 and $15.35, with adjusted diluted EPS ranging from $17.25 to $17.75[35]. Asset and Cash Position - Total assets as of February 28, 2026, were $4,219,830, down from $4,304,272 as of August 31, 2025[28]. - Cash and cash equivalents decreased to $268,338 as of February 28, 2026, from $337,651 as of August 31, 2025[28]. - The company reported a net cash provided by operating activities of $332,972 for the six months ended February 28, 2026, compared to $260,327 in 2025[29]. - The company’s total stockholders' equity decreased to $2,129,112 as of February 28, 2026, from $2,186,413 as of August 31, 2025[28]. Strategic Initiatives - A multi-year strategic agreement was announced with Barclays to provide access to FactSet's financial data and analytics, enhancing market data strategy[17]. - The launch of AI Doc Ingest for Cobalt aims to improve data extraction for private capital clients, indicating a focus on AI-driven solutions[17]. ASV Performance - Organic ASV reached $2,449.1 million, up 6.7% year over year, with a net increase of $152.9 million compared to the prior year[5][8]. - ASV from the Americas was $1,605.9 million, reflecting a 7.0% increase year over year, while EMEA and Asia Pacific ASV grew by 4.3% and 10.0%, respectively[9][10][11].

Financial Performance - Net sales for Q4 FY2025 decreased by 3.1% to $138.4 million compared to $142.8 million in Q4 FY2024[4] - Total company comparable sales decreased by 4.8% in Q4 FY2025[4] - Direct to consumer net sales, which represented 53.5% of net sales, increased by 2.6% compared to Q4 FY2024[4] - Net sales for the thirteen weeks ended January 31, 2026, were $138,410,000, a decrease of 3.0% from $142,842,000 for the same period in 2025[28] - Gross profit for the fifty-two weeks ended January 31, 2026, was $409,745,000, down from $429,856,000, reflecting a decrease of 4.7%[31] - Operating income for the fifty-two weeks ended January 31, 2026, was $50,610,000, a decline of 33.1% compared to $75,702,000 for the previous year[31] - For the fifty-two weeks ended January 31, 2026, net income was $27,891,000, down from $39,483,000 in the prior year[42] Losses and Income - Net loss for Q4 FY2025 was $3.5 million, compared to net income of $2.2 million in Q4 FY2024[4] - Net loss for the thirteen weeks ended January 31, 2026, was $3,521,000, compared to a net income of $2,248,000 for the same period in 2025[28] - Adjusted net loss income for the thirteen weeks was $(287,000), compared to adjusted net income of $5,012,000 in the prior year[49] - The company incurred a loss on debt refinancing of $3,116,000 during the thirteen weeks ended January 31, 2026[36] Cash Flow and Liquidity - Free Cash Flow for the fifty-two weeks ended January 31, 2026, is presented as a supplemental measure to assess liquidity, reflecting cash flow from operations less capital expenditures[23] - For the thirteen weeks ended January 31, 2026, net cash used in operating activities was $(1,605) million, a significant decrease from $8,089 million for the same period in 2025[61] - For the fifty-two weeks ended January 31, 2026, net cash provided by operating activities was $42,144 million, down from $65,036 million in 2025[64] - Free cash flow for the thirteen weeks ended January 31, 2026, was $(11,710) million, compared to $381 million for the same period in 2025[63] - Free cash flow for the fifty-two weeks ended January 31, 2026, was $23,229 million, a decrease from $47,281 million in 2025[64] Assets and Liabilities - Total assets increased to $450,216,000 as of January 31, 2026, compared to $417,699,000 as of February 1, 2025[33] - Total liabilities rose to $328,717,000 as of January 31, 2026, up from $311,930,000 the previous year[33] Dividends - The board declared a cash dividend of $0.09 per share, reflecting a 12.5% increase over the previous dividend[12] - Cash dividends declared per common share increased to $0.32 for the fifty-two weeks ended January 31, 2026, compared to $0.21 in the prior year[31] Operational Developments - The company opened seven new stores in Q4 FY2025, ending the year with 256 stores[7] - The company is implementing new technology, including a predictive AI-powered inventory forecasting model, to enhance operational efficiency and customer engagement[24] Adjusted Metrics - Adjusted EBITDA for FY2026 is projected to be between $15 million and $17 million[20] - Adjusted EBITDA for the same period was $7,168,000, with an adjusted EBITDA margin of 5.2%, down from $14,501,000 and 10.2% respectively in the prior year[36] - Adjusted EBITDA for the fifty-two weeks was $84,342,000, with an adjusted EBITDA margin of 14.1%, compared to $107,140,000 and 17.5% in the previous year[42] - Adjusted Net Income per Diluted Share for the fifty-two weeks ended January 31, 2026, was $1.82, down from $2.61 in the previous year[31] - The adjusted net income per share for the fifty-two weeks was $2.47, down from $3.51 in the previous year[55] Inventory and Cash Management - Inventory at the end of Q4 FY2025 was $70.1 million, up from $61.3 million at the end of Q4 FY2024[6] - The total cash, cash equivalents, and restricted cash at the end of the period on January 31, 2026, was $41,378 million, compared to $35,790 million on February 1, 2025[62] - The beginning cash and cash equivalents for the fifty-two weeks ended January 31, 2026, was $35,790 million, down from $62,540 million in 2025[64] - The company recorded a decrease in restricted cash of $5 million for the fifty-two weeks ended January 31, 2026[61] - The company’s cash and cash equivalents decreased by $16,991 million for the thirteen weeks ended January 31, 2026, compared to a decrease of $3,338 million in 2025[61]

Revenue Performance - Full year 2025 revenue reached $90.9 million, a 3.5% increase from $86.9 million in 2024[1] - Fourth quarter 2025 revenue was $48.3 million, up 21.6% from $39.7 million in Q4 2024, and up significantly from $6.3 million in Q3 2025[1][5] - Total revenue for the year ended December 31, 2025, was $90,907,000, representing an increase of 3.4% from $86,935,000 in 2024[31] - For the three months ended December 31, 2025, revenue was $48,278,000, an increase from $39,729,000 in the same period of 2024[31] Profitability - Gross profit for the full year was $54.4 million, with a gross margin of 59.9%, down from 67.1% in 2024[12][13] - Gross profit decreased to $54,415,000 in 2025, down 6.5% from $58,317,000 in 2024[31] - Operating loss for the year was $(28.8) million, compared to $(17.4) million in 2024[13] - Net loss for 2025 was $(4.1) million, an improvement from $(38.7) million in 2024[14] - Net loss for the year ended December 31, 2025, was $4,104,000, a significant improvement compared to a net loss of $38,694,000 in 2024[31] - The company reported a net loss margin of (4.5)% for the year ended December 31, 2025, compared to (44.5)% in 2024, indicating improved profitability[33] Expenses and Costs - Total operating expenses increased to $83,180,000 in 2025, up 9.3% from $75,750,000 in 2024, primarily due to higher research and development costs[31] - Adjusted EBITDA for 2025 was $5.7 million, down from $33.7 million in 2024[16] - Adjusted EBITDA for the year was $5,658,000, down from $33,690,000 in 2024, reflecting changes in operational efficiency[33] Financial Position - Cash position as of December 31, 2025, was $74.4 million[17] - Total current assets increased to $106,476,000 in 2025, compared to $42,595,000 in 2024, indicating improved liquidity[28] - Total liabilities decreased to $34,947,000 in 2025 from $152,269,000 in 2024, showing a significant reduction in financial obligations[29] - Cash reserves rose to $74,358,000 in 2025, up from $20,741,000 in 2024, enhancing the company's financial stability[28] Future Outlook - The company expects 2026 revenue growth of 15% to 25% year-over-year, supported by a backlog of approximately $150 million as of March 31, 2026[18][19] - The company completed its first U.S.-manufactured RQ-35 Heidrun ISR drones and is targeting Blue UAS certification in the first half of 2026[11]

FOR IMMEDIATE RELEASE McCORMICK REPORTS STRONG FIRST QUARTER PERFORMANCE AND REAFFIRMS 2026 OUTLOOK Sales Metrics | | | | First Ouarter 2026 | | | | | --- | --- | --- | --- | --- | --- | --- | | | As | | Organic(1) | | Acquisition | Constant | | | Reported | | | | | Currency | | | % Change | Volume/ Mix | Price | % Change | % Change | % Change | | Total Net Sales | 16.7 % | (0.7)% | 1.9 % | 1.2 % | 12.4 % | 13.6 % | | Total Consumer | 24.5 % | (0.4)% | 2.2 % | 1.8 % | 19.8 % | 21.6 % | | Americas | 30.4 % | ...

FOR IMMEDIATE RELEASE HUNT VALLEY, Md., March 31, 2026 - McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today reported financial results for the first quarter ended February 28, 2026 and reaffirmed its outlook for fiscal 2026. Chairman, President, and CEO's Remarks Brendan M. Foley, Chairman, President, and CEO, stated, "We are pleased to begin the year with first quarter results that demonstrate the strength and resilience of our business. We delivered strong growth in sales, adju ...

Stock Split and Corporate Changes - The Company executed a reverse stock split at a ratio of 1-for-12, reducing authorized shares from 300 million to 25 million and outstanding shares from 151.7 million to 12.6 million [12][14]. - The reverse stock split and name change to "Meridian Holdings Inc." became effective on March 3, 2026 [13]. - No fractional shares were issued; stockholders entitled to fractional shares received cash based on the closing sale price prior to the effective time [14]. - The conversion ratio for preferred stock and the number of shares issuable upon exercise of stock options were adjusted proportionately in line with the 1-for-12 split [16]. - The exercise price for outstanding stock options and warrants was increased in inverse proportion to the split ratio, maintaining the aggregate exercise price [16]. - The effects of the reverse split and name change have been retroactively reflected throughout the report [17]. Financing and Growth - The Company anticipates the need for significant additional financing to support growth, acquisitions, and operational expansion [20]. - The Company requires significant additional financing to grow and expand operations, complete acquisitions, and pay post-closing amounts related to the MeridianBet Group acquisition [20]. Risks and Uncertainties - Risks include potential dilution from the conversion of outstanding debt and preferred stock, as well as challenges in completing acquisitions [20]. - Risks include dilution from the conversion of outstanding debt, preferred stock, and warrants, as well as potential disruptions caused by acquisitions [20]. - The Company faces risks related to gaming fraud, user cheating, and cybersecurity threats [21]. - The Company faces risks associated with gaming fraud, user cheating, and cyber-attacks [21]. - There are concerns regarding systems failures and technology infrastructure that the Company's programs rely on, including cybersecurity and hacking risks [22]. - Forward-looking statements are subject to various risks and uncertainties that may cause actual results to differ materially from projections [19][24]. - Forward-looking statements are inherently uncertain and should not be relied upon excessively by investors [23]. - The Company has no obligation to update or revise forward-looking statements unless required by law [24].

Enrollment and Revenue - For the fiscal year ended December 31, 2025, the company had 4,127 students enrolled, with 57% in portfolio training programs[23] - Net revenues for the fiscal years ended December 31 were RMB221.6 million in 2023, RMB268.1 million in 2024, and RMB268.1 million ($38.3 million) in 2025[23] - Net revenues for 2024 reached RMB 268,060,162, a 21% increase from RMB 221,618,968 in 2023[72] - The net loss for 2024 was RMB 36,097,872, slightly improved from a net loss of RMB 33,710,541 in 2023[72] - The company’s total current assets in 2024 were RMB 111,367,124, a decrease from RMB 66,639,674 in 2025[76] Financial Performance - For the fiscal year ended December 31, 2025, the Company reported net revenues of RMB 268.1 million, with total costs and expenses amounting to RMB 332.4 million, resulting in a net loss of RMB 48.0 million[70] - The Company incurred a goodwill impairment of RMB 33.9 million in the fiscal year ended December 31, 2025[70] - Total cost and expenses for 2024 were RMB 311,279,249, compared to RMB 263,145,737 in 2023, reflecting an 18% increase[72] - The company reported a significant investment loss of RMB 29,233,857 in 2024, compared to a loss of RMB 28,469,235 in 2023[72] Regulatory Environment - The variable interest entity (VIE) structure involves unique risks, including potential disallowance by PRC regulatory authorities, which could materially affect operations and the value of ADSs[24] - The company is subject to complex and evolving PRC laws and regulations, which could adversely affect its business operations and reputation[25] - The Company believes it is not required to obtain permission or approval from the CSRC for its listing on Nasdaq, but future compliance with the Crackdown Opinions remains uncertain[45] - The PRC regulatory environment for private education institutions is evolving, with new requirements for operating permits for non-academic after-school tutoring institutions, particularly in provinces like Guangdong and Liaoning[172] Business Operations - The company is exploring acquisition opportunities in the international education sector to broaden its service spectrum[22] - The company has established 19 training centers in China as of March 20, 2026, with the first center opened in 2012[113] - The company is focusing on developing and expanding its small-sized class model and online-merge-offline model to improve profit margins[115] - The company has made strategic investments in complementary businesses, but past investments have been fully impaired, raising concerns about future acquisitions[122] Cash Flow and Dividends - The Company did not distribute any dividends to its shareholders for the fiscal years ended December 31, 2023, 2024, and 2025, and future dividend payments will depend on various factors including operations and earnings[64] - The Company faces restrictions on cash transfers between entities and to U.S. investors, which may impact its ability to pay dividends or service debt[66] - Under PRC law, dividends from PRC subsidiaries can only be paid out of accumulated after-tax profits, which may limit the Company's ability to distribute earnings[157] Risks and Challenges - The company may face challenges in generating sufficient net income to sustain continued expansion, which could impact financial performance[97] - A decline in market acceptance or growth of the company's products and services could lead to decreased revenues, particularly in creative arts-related international education services[104] - The company faces increasing competition from both established brands and new entrants, which may negatively affect revenues and market share[128] - The company may experience declines in student enrollment due to geopolitical uncertainties and economic slowdowns affecting international study[119] Compliance and Cybersecurity - The evolving data security regulations in China, including the Cyber Security Law and the Personal Information Protection Law, impose significant obligations on network operators regarding the protection of personal information[177] - The company has implemented various security measures to protect user information but cannot guarantee that these measures will be sufficient to prevent data breaches[177] - The company has not received any inquiries, notices, warnings, sanctions, or regulatory objections from the national cyberspace authorities regarding personal information protection compliance[181] Corporate Structure - The Company adopts a holding company structure and may rely on dividends and distributions from its PRC subsidiaries for cash requirements[51] - The Company is classified as a Cayman Islands holding company, with nearly all business operations conducted in mainland China, which may classify it as an "indirect issuance of securities overseas" under new regulations[153] - The VIE is 90% owned by the Chairman and 10% by the President, and the Company has contractual arrangements to direct the activities of the VIE[218] Audit and Accounting - The company appointed Audit Alliance LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2023[86] - The PCAOB has secured complete access to inspect and investigate registered public accounting firms in mainland China and Hong Kong, which interrupted the calculation of the consecutive period to trigger trade prohibition for the Company[204] - The Company is subject to potential delisting of its ADSs if the PCAOB cannot conduct full inspections of its auditor in the future, which may adversely affect the value of investments[205]

Financial Performance - Total revenue for Q4 2025 was $16.0 million, a decrease of 4% from Q4 2024, primarily due to a $2.6 million decline in system revenue, partially offset by a $1.8 million increase in revenue from higher worldwide procedure volume[3]. - Total revenue for Q4 2025 was $16,025,000, a decrease of 4.23% from $16,731,000 in Q4 2024[26]. - Recurring revenue for the full year 2025 exceeded $46.3 million, reflecting a 15% increase over 2024, with 79% of total revenue for both Q4 and the full year coming from recurring sources[2][6]. - Product revenue for the twelve months ended December 31, 2025, was $45,928,000, an increase of 11.00% compared to $41,065,000 in 2024[26]. - The net loss for Q4 2025 was $1.5 million, or ($0.12) per share, a significant improvement from a net loss of $18.7 million, or ($1.61) per share, in Q4 2024[9]. - Net loss for Q4 2025 was $1,458,000, compared to a net loss of $18,702,000 in Q4 2024[26]. - Adjusted EBITDA for Q4 2025 was $0.6 million, compared to $0.5 million in Q4 2024, indicating a positive trend in operational performance[10][22]. - Adjusted EBITDA for Q4 2025 was $595,000, up from $478,000 in Q4 2024[24]. Operational Metrics - In Q4 2025, LENSAR placed 15 ALLY Robotic Cataract Laser Systems, increasing the installed base to approximately 200 systems, a 48% growth compared to the end of 2024[4]. - Worldwide procedure volume increased by approximately 20% in Q4 2025 compared to Q4 2024, with a total of 206,014 procedures performed in 2025, up from 169,506 in 2024[3][6]. - The total combined installed base of LENSAR Laser Systems and ALLY Systems reached approximately 435 systems as of December 31, 2025, representing a 13% increase from the previous year[5]. - The company has a backlog of 13 ALLY Systems pending installation as of December 31, 2025, indicating ongoing demand for its products[4]. Expenses and Liabilities - Selling, general and administrative expenses rose to $10.3 million in Q4 2025, a 51% increase from $6.8 million in Q4 2024, largely due to acquisition-related costs[6][8]. - Selling, general and administrative expenses for the twelve months ended December 31, 2025, were $45,157,000, an increase of 70.50% from $26,488,000 in 2024[26]. - Research and development expenses for the twelve months ended December 31, 2025, were $5,622,000, slightly up from $5,329,000 in 2024[26]. - Total current assets increased to $46,771,000 in 2025 from $41,979,000 in 2024, reflecting a growth of 11.00%[28]. - Total liabilities rose significantly to $83,665,000 in 2025, compared to $47,651,000 in 2024, marking a 75.61% increase[28]. - Cash and cash equivalents decreased to $12,974,000 in 2025 from $16,263,000 in 2024, a decline of 20.00%[28]. - As of December 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $18.0 million, down from $22.5 million at the end of 2024[11].

Product Development - NeOnc is developing two lead products: NEO100, which is in Phase IIa trials, and NEO212, which has received IND approval and is set to begin clinical trials in Q4 2023[22][26]. - The Phase IIa trial for NEO100 has expanded eligibility to include patients with recurrent Grade III IDH1/2 mutant astrocytomas, increasing the potential enrollment pool significantly[24]. - NEO212 has established a recommended Phase 2 dose of 610 mg, with preliminary observations suggesting anti-tumor activity in heavily pretreated patients[27]. - The ongoing Phase IIa trials aim to confirm dosing requirements and assess the drug's performance in a larger patient population[52]. - The company is also conducting a Phase I/II trial for oral NEO212, targeting various solid tumors with brain metastases[69]. - NEO212 has received FDA approval for oral administration in 2023, enabling Phase I/IIa clinical trials focusing on patients with intracranial malignancies[79]. Clinical Trial Results - In the Phase I trial of NEO100, 21% of patients showed radiographic responses, exceeding the historical response rates of <8% for recurrent high-grade gliomas[25]. - NEO100's Phase I trial demonstrated that 37% of patients were alive two years after treatment, compared to an average life expectancy of six months for recurrent glioblastoma patients[35]. - In a Phase I trial, 25% of patients with recurrent glioblastoma survived for at least 4 years, indicating preliminary signs of activity for NEO100[41][44]. - Among 12 patients in the Phase I trial, 55% survived more than one year, and 33% survived over two years[44]. - The Phase IIa study for NEO100 includes 25 patients with recurrent glioblastoma and aims to evaluate progression-free survival at six months[53][54]. - In a Phase I clinical trial, intranasal NEO100 demonstrated a progression-free survival (PFS-6) rate of 33% and an overall survival (OS-12) rate of 55% among 12 patients[100]. - The ongoing Phase 1/2a study of intranasal NEO100 has enrolled 25 patients, with 24% showing radiographic responses and 44% achieving progression-free survival at six months[103]. Drug Delivery Methods - NEO100 is being investigated for its potential to bypass the blood-brain barrier (BBB) for drug delivery, with proof of concept observed in animal models but not yet in humans[40]. - NEO100's intranasal delivery method allows for convenient administration at home, avoiding invasive procedures[51]. - NEO100's intranasal delivery method allows for direct brain access, potentially avoiding the blood-brain barrier and reducing systemic side effects[86]. - The company is exploring three drug delivery pathways using NEO100, with intranasal delivery being the only one currently in clinical testing[83]. - Intra-arterial delivery of NEO100 demonstrated the ability to open the blood-brain barrier, allowing therapeutic agents to enter the brain in mouse models[119]. Market Potential - The global CNS treatment market is projected to grow at a CAGR of 8.6% to reach $267.6 billion by 2034, while the brain tumor drug market is expected to grow at a CAGR of 9.8% to reach $4.6 billion by 2032[91]. - The GBM drug market is anticipated to grow at a CAGR of 9.8% to $4.4 billion by 2023, driven by an increasing geriatric population and rising incidence rates[92]. - The average life expectancy for patients with newly-diagnosed glioblastoma is currently only 15 months, highlighting the urgent need for effective treatments like NEO212[137]. Regulatory and Compliance - The company has no commercial products or sales infrastructure, and must conduct clinical trials to obtain regulatory approvals[28]. - The FDA regulates the approval process for new drug products, requiring substantial time and financial resources for compliance with testing and manufacturing standards[183][184]. - The company must submit a new drug application (NDA) to the FDA, which includes evidence of safety and efficacy from clinical trials, before marketing any new drug product[189]. - The FDA requires extensive monitoring and auditing of clinical activities, with annual progress reports detailing clinical trial results submitted to the FDA[192]. - Manufacturers must comply with cGMP regulations, including quality control and assurance, to maintain product safety and efficacy[216]. Intellectual Property - The company holds exclusive rights to 28 issued patents and 14 pending patent applications in the U.S., with a total of 65 issued patents and 28 pending applications internationally[147]. - The company has filed multiple patent applications for its product candidates, including NEO100 and NEO212, with expiration dates ranging from 2031 to 2038[150]. - The company is responsible for all reasonable patent expenses incurred by USC for filing, prosecution, and maintenance of the licensed patents[157]. - The patent prosecution process is complex and may require narrowing claims, which could limit the scope of patent protection[153]. Financial Obligations - The company has a litigation settlement payable of $4 million to OEP, which is recorded in the consolidated balance sheets as of December 31, 2025 and 2024[169]. - The company has settled a dispute with Fox Infused for $600,000, payable within 5 business days of the closing date of the initial public offering, with accumulated interest of 10% per annum for any default[179]. - The company must pay USC $230,000 by March 31, 2024, to satisfy prior unpaid sublicense issue royalties and annual maintenance royalties due for sublicensees[166]. Competitive Landscape - The competitive landscape for CNS treatments includes established players like Pfizer, Roche, and Novartis, as well as emerging therapies such as gene therapies and biologics[138][141]. - The company is investigating additional proprietary chemotherapy agents that have shown positive effects in laboratory tests for various cancers, including NEO212 for brain cancer[149]. Future Strategies - Future growth strategies include potential commercial launch of NEO100 following FDA approval and exploration of pediatric indications for NEO100[149]. - The company aims to change the cancer therapeutic landscape by developing novel drug delivery methods combined with new drug candidates[94].